MUC16 and neoplasm: Traditional biomarkers, such as CA125 and HE4, remain integral to diagnosis and monitoring, but emerging biomarkers, including homologous recombination deficiency (HRD), PD-L1 expression, and tumor mutation burden (TMB), are reshaping therapeutic approaches [8,9,10].